Loading patent…
AssigneeKorea Institute of Radiological & Medical Sciences
InventorsYoon Jin Lee, Yun-Sil Lee, Hae-June Lee, Seo-Hyun Choi, Kyeng-Jung Kim
Estimating the term…
The present invention relates to a pharmaceutical composition for promoting angiogenesis, containing an antibody that specifically binds to heat shock protein (HSP) 27. In addition, the present invention relates to a pharmaceutical composition containing an antibody that specifically binds to HSP 27, for treating an angiogenesis-dependent ailment selected from a group consisting of a wound, chronic ulcer, ischemic stroke, myocardial infarction, angina pectoris, and cerebrovascular dementia. In addition, the present invention relates to a method for promoting the in vitro growth of endothelial cells using an antibody that specifically binds to HSP27. In addition, the present invention relates to a method for screening for active substances for promoting angiogenesis or for active substances for treating an angiogenesis-dependent ailment, the method comprising the following steps: treating vascular endothelial cell lines with each specimen; measuring the content of HSP27 in the respective vascular endothelial cell lines; and selecting a specimen in which the HSP27 content in the vascular endothelial cell lines are decreased as compared to a control group.
A method for promoting angiogenesis or treating an angiogenesis-dependent ailment, the method comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an antibody that specifically binds to heat shock protein 27 (HSP27).
A method of promoting growth of vascular endothelial cells in vitro by using an antibody that specifically binds to heat shock protein 27 (HSP27), comprising contacting vascular endothelial cells in vitro with HSP27, thereby inhibiting growth of the vascular endothelial cells.
A method for screening for active substances for promoting angiogenesis, the method comprising:
A method for screening for active substances for treating an angiogenesis-dependent ailment selected from the group consisting of a wound, chronic ulcer, ischemic stroke, myocardial infarction, angina pectoris, and cerebrovascular dementia, the method comprising:
Dependencies are inferred from the claim text.